Research, Instrumentation & New Product Development

We are actively exploring the development of new diagnostic and therapeutic radiopharmaceuticals. Our current R&D focuses include advanced PET tracers such as FAPI and emerging therapeutic isotopes including Lu-177, Ac-225, and Tb-161. By expanding our research in these areas, we aim to broaden clinical applications in oncology, improve treatment precision, and enhance patient care. These initiatives reaffirm our commitment to advancing innovative solutions that address evolving medical needs in diagnostics and targeted radionuclide therapies.